drugset / Trial / NCT05395052
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Timeline
- Start
- 2022-05-31
- Primary completion
- 2023-08-11
- Completion
- 2023-08-11
Outcome
Outcome not reported
Stopped: “This study was terminated by the Sponsor.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amivantamab | Monoclonal antibody | — | — |
| Subject | Atezolizumab | Monoclonal antibody | — | — |
| Subject | Avelumab | Monoclonal antibody | — | — |
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Subject | FT536 | Cell therapy | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |
| Background | IL-2 | Protein / enzyme biologic | — | — |